Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Senhwa Biosciences

Request full access

Drug development company creating innovative therapies for cancer and related diseases

Taipei, TaiwanFounded 2013Biotech & Life Sciences

About Senhwa Biosciences

Senhwa Biosciences, Inc., founded in 2012 by Co-founder, President, and CEO Dr. Tai-Sen Soong, is a clinical-stage biopharmaceutical company specializing in the development of targeted therapies for oncology. The company operates with a strategic focus on DNA Damage Response (DDR), aiming to exploit the vulnerabilities of cancer cells. Headquartered in New Taipei City, Taiwan, with a key operational subsidiary in San Diego, California, Senhwa is publicly traded on the Taipei Exchange (TPEx: 6492).

The company's business model centers on identifying and advancing promising drug candidates through to clinical proof-of-concept, a strategy designed to de-risk development and efficiently use resources from the global pharmaceutical ecosystem. Senhwa's revenue is primarily generated through partnerships, licensing agreements, and collaborations with research institutions. A significant milestone was achieved in December 2013 when the company raised $17 million in a Series B financing round, enabling the progression of its key assets into clinical trials.

Senhwa's drug pipeline is led by two first-in-class small molecule compounds, Pidnarulex (CX-5461) and Silmitasertib (CX-4945). Pidnarulex is an investigational drug that functions by stabilizing G-quadruplex (G4) structures in the DNA of cancer cells. This action is designed to trigger replication-dependent DNA damage, leading to cancer cell death, particularly in tumors with BRCA1/2 mutations or other homologous recombination deficiencies (HRD). The U.S. National Cancer Institute (NCI) is sponsoring clinical trials for CX-5461 in advanced solid tumors and MYC-aberrant lymphoma, which significantly reduces Senhwa's R&D expenditures.

Silmitasertib (CX-4945) is a selective inhibitor of the CK2 protein kinase, which plays a role in DNA repair mechanisms. By inhibiting CK2, Silmitasertib enhances the efficacy of DNA-damaging chemotherapy agents. Clinical trials are evaluating its potential in treating cholangiocarcinoma and basal cell carcinoma, with promising results in patients who have failed other therapies. Beyond oncology, interim findings have prompted a strategic shift to explore CX-4945's potential as a treatment for HIV, with plans for a new formulation to improve patient tolerability.

The management team, led by Chairman Mr. Benny T. Hu and CEO Dr. Tai-Sen Soong, possesses extensive experience in drug development, investment, and corporate management. Dr. Soong has a 30-year background in life science operations and investment, including leadership roles at CDIB and founding roles in other pharmaceutical ventures. Mr. Hu is a seasoned entrepreneur and professional manager, previously leading China Development Industrial Bank (CDIB) and expanding its investment portfolio significantly.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2017
Employees
31
Open positions
None listed
Dealroom signal
30.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Jul 2026 $16M — Global Emerging Markets ↗
IPO✓Exit Apr 2017 $45M — Undisclosed ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Senhwa Biosciences website traffic

Latest recorded traffic for Senhwa Biosciences is 190 monthly website visits, down 88.8% over the last three months. Senhwa Biosciences's team grew 0% over the past year.

Latest monthly visits190 3-month web change-88.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Senhwa Biosciences in the Taipei ecosystem

Live from Dealroom

The Senhwa Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later1 investor entered at this stage

  • Global Emerging Markets

Other known investors2 additional known investors

  • Black Marble Capital Management
  • Cathay Venture
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇹🇼 Taiwan69.6%
🇺🇸 United States13%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Senhwa Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Senhwa Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.